RecruitingPhase 1NCT07313813

A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus


Sponsor

Eli Lilly and Company

Enrollment

20 participants

Start Date

Dec 29, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal. Ultrasound devices will be used to check the stomach content after a test meal. The study can last approximately 28 weeks.


Eligibility

Min Age: 21 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study examines how long patients with type 2 diabetes should fast before surgery when they are taking a GLP-1 medication like dulaglutide (Trulicity), and whether stopping the drug beforehand helps the stomach empty properly before anaesthesia. This is important because GLP-1 drugs slow digestion, which can be a risk during surgery. **You may be eligible if...** - You have had type 2 diabetes for at least 6 months - Your diabetes is managed with diet and exercise, metformin, or one additional oral medication (DPP-4 or SGLT-2 inhibitor) - Your HbA1c (a measure of blood sugar control) is between 6.5% and 10% **You may NOT be eligible if...** - You have a known stomach condition or history of significant gastrointestinal surgery - You have poorly controlled diabetes outside the accepted range - You are on insulin or other diabetes medications not allowed by the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDulaglutide

Administered SC


Locations(1)

Lilly Centre for Clinical Pharmacology

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07313813


Related Trials